Literature DB >> 18600533

Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin.

G Codacci-Pisanelli1, P Noordhuis, C L van der Wilt, G J Peters.   

Abstract

Fluorouracil (5FU) acts by RNA-incorporation and inhibition of thymidylate synthase; the first action is counteracted by uridine, and the second is enhanced by leucovorin (LV). Growth inhibition of C26-10 colon cancer cells by 5FU was enhanced by LV and rescued by uridine, but 5FU-LV was only partially rescued by uridine. In WiDr cells, 5FU sensitivity was not enhanced by LV, while both 5FU and 5FU-LV were rescued by uridine. Intermediate trends were found in SW948 and HT29 cells. Uridine rescue in mice allowed 1.5-fold increase in 5FU dose, leading to 2-fold increase in the antitumor effect and thymidylate synthase inhibition in resistant Colon-26 tumors. In the sensitive Colon-26-10 tumor, uridine rescue decreased 5FU-RNA incorporation > 10-fold, without affecting the antitumor activity. The use of LV and uridine can differentiate between two mechanisms of action of 5FU.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600533     DOI: 10.1080/15257770802145496

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  4 in total

1.  A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma.

Authors:  Sezer Saglam; N Faruk Aykan; Burak Sakar; Mine Gulluoglu; Emre Balik; Hasan Karanlik
Journal:  J Gastrointest Oncol       Date:  2011-03

2.  AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.

Authors:  William H Gmeiner; Jonathan R Brody; Alex O Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C Agostini; Talia Golan; Komaraiah Palle; Charles J Yeo
Journal:  Mol Cancer Res       Date:  2021-02-16       Impact factor: 6.333

3.  Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.

Authors:  Anthony Dominijanni; William H Gmeiner
Journal:  Cancer Drug Resist       Date:  2018-03-19

4.  Genome-wide CRISPR Screening Reveals Pyrimidine Metabolic Reprogramming in 5-FU Chronochemotherapy of Colorectal Cancer.

Authors:  Ya Niu; Xinyi Fan; Yaping Wang; Jiaxin Lin; Luchun Hua; Xiaobo Li; Ruizhe Qian; Chao Lu
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.